Imidapril: Will fewer adverse events translate into better long-term outcomes?

Drugs

Volumn 67, Issue 9, 2007, Pages 1379-1382

  Richart, Tom ^a   Staessen, Jan A ^a   Birkenhäger, Willem H ^b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; FOSINOPRIL; IMIDAPRIL; IMIDAPRILAT; LISINOPRIL; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL;

ANGIONEUROTIC EDEMA; ASPHYXIA; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG TOLERABILITY; DYSGEUSIA; HEART FAILURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; NONHUMAN; NOTE; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; CLINICAL TRIALS; HUMANS; HYPERTENSION; IMIDAZOLIDINES; TREATMENT OUTCOME;

EID: 34249945285     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200767090-00009     Document Type: Note

References (32)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. National High Blood Pressure Education Program Coordinating Committee. JAMA 2003 May 21; 289 (19): 2560-72
2. Zhang H, Thijs L, Staessen JA. Blood pressure lowering for primary and secondary prevention of stroke. Hypertension 2006 Aug; 48 (2): 187-95
3. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. European Society of Hypertension-European Society of Cardiology Guidelines Committee [published erratum appears in J Hypertens 2003 Nov; 21 (11): 2203-4 and J Hypertens 2004 Feb; 22 (2): 435]. J Hypertens 2003 Jun; 21 (6): 1011-53
4. National Collaborating Centre for Chronic Conditions. Hypertension: management of hypertension in adults in primary care: partial update. London: Royal College of Physicians, 2006 [online]. Available from URL: http://www.nice.org.uk/download.aspx?o=CG034fullguideline [Accessed 2006 Aug 10]
5. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2002 Dec 18; 288 (23): 2981-97
6. Leenen FH, Nwachuku CE, Black HR, et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension 2006 Sep; 48 (3): 374-84
7. Robinson DM, Curran MP, Lyseng-Williamson KA. Imidapril: a review of its use in essential hypertension, type 1 diabetic nephropathy and chronic heart failure. Drugs 2007; 67 (8): 1359-78
8. Sakamoto KI, Sugimoto KI, Fujimura A. Different inhibition of enalaprilat and imidaprilat on bradykinin metabolizing enzymes. Life Sci 2000; 67 (18): 2159-65
9. Matsubara S, Kikkawa H, Kaminuma O, et al. Angiotensin-converting enzyme inhibitors can potentiate ozone-induced airway hyperresponsiveness. Eur J Pharmacol 1997 Oct 22; 337 (2-3): 259-65
10. Silveria P, Vaz-da-Silva M, Maia J, et al. Effects of enalapril and imidapril in the capsaicin cough challenge test and spirometry parameters in healthy volunteers. Therapy 2004; 1 (2): 223-30
11. van Veldhuisen DJ, Genth-Zotz S, Brouwer J, et al. High-versus low-dose ACE inhibition in chronic heart failure: a double-blind, placebo-controlled study of imidapril. J Am Coll Cardiol 1998 Dec; 32: 1811-8
12. Messerli FH, Nussberger J. Vasopeptidase inhibition and angiooedema. Lancet 2000 Aug 19; 356 (9230): 608-9
13. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000 Jan 20; 342 (3): 145-53
14. Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. J Forensic Sci 2001 Sep; 46 (5): 1239-43
15. Nakagawa T, Ohrui T, Sekizawa K, et al. Sputum substance P in aspiration pneumonia [letter]. Lancet 1995 Jun 3; 345 (8962): 1447
16. Nakagawa T, Sekizawa K, Arai H, et al. High incidence of pneumonia in elderly patients with basal ganglia infarction. Arch Intern Med 1997 Feb 10; 157 (3): 321-4
17. Arai T, Sekizawa K, Ohrui T, et al. ACE inhibitors and protection against pneumonia in elderly patients with stroke. Neurology 2005 Feb 8; 64 (3): 573-4
18. Song JC, White CM. Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet 2002; 41 (3): 207-24
19. Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int 2000; 17 (2): 209-19
20. Staessen J, Lijnen P, Fagard R, et al. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981 Dec; 91 (3): 457-65
21. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res 2001 Jan-Feb; 29 (1): 13-21
22. Harder S, Thürmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997 May; 43: 475-80
23. Data on file, Tanabe Europe N.V. Summary of product characteristics: Tanatril 5 mg tablet. 2002 Nov 11
24. Wong J, Patel RA, Kowey PR. The clinical use of angiotensin-converting enzyme inhibitors. Prog Cardiovasc Dis 2004 Sep-Oct; 47 (2): 116-30
25. Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 2005 Dec 10; 366 (9502): 2026-33
26. Verdecchia P, Reboldi G, Angeli F, et al. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension 2005 Aug; 46 (2): 386-92
27. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998 Sep 12; 317 (7160): 713-20
28. Hansson L, Lindholm LH, Niskanen L, et al. Effect of angiotensin- converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999 Feb 20; 353 (9153): 611-6
29. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003 Sep 6; 362 (9386): 782-8
30. Weinberger J. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Curr Cardiol Rep 2003 Mar; 5 (2): 139-40
31. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000 Apr 19; 283 (15): 1967-75
32. Verma S, Strauss M. Angiotensin receptor blockers and myocardial infarction. BMJ 2004 Nov 27; 329 (7477): 1248-9